Introduction
Like many rare disorders, congenital lipoid adrenal hyperplasia (lipoid CAH) was largely overlooked for many years. Recent developments have revealed the molecular pathophysiology of this disorder, providing novel insights into the regulation of steroid hormone biosynthesis and into developmental and reproductive endocrinology.
History
Lipoid CAH was first described in detail as an inherited endocrine disorder by Prader and colleagues (Prader & Gurtner 1955 , Prader & Siebenmann 1957 , Prader & Anders 1962 , although at least four autopsy cases appeared earlier in the pathology literature (Tilp 1913 , Brutschy 1920 , Zahn 1948 , Sandison 1955 ). Prader's group described male pseudohermaphroditism, an apparent lack of adrenal steroids and accumulation of lipid deposits in the adrenal, inherited in an autosomal recessive fashion. Written in German, Prader's work was not widely recognized until Camacho et al. (1968) reported an apparently milder case, with the onset of clinically apparent salt loss at 8 months of age, and postulated that the disorder was in one of the enzymes involved in the conversion of cholesterol to pregnenolone. However, the nature of the defect was unclear, in part because the enzymology of the conversion of cholesterol to pregnenolone was unclear. At that time it was thought that the conversion of cholesterol to pregnenolone required at least three enzymes, a 20 -hydroxylase, a 22-hydroxylase, and a 20,22 desmolase (Shimizu et al. 1961) , and that lipoid CAH was due to a defect in one of these enzymes. Degenhart et al. (1972) were the first to study lipoid CAH in vitro, by comparing the production of pregnenolone by mitochondria from the adrenals of affected and unaffected infants. Mitochondria from affected tissue could not convert cholesterol to pregnenolone (although normal mitochondria could), but affected mitochondria could convert 20 -hydroxycholesterol to pregnenolone. They logically concluded that the defect was in a specific 20 -hydroxylase; this conclusion was incorrect, but the experimental design was prescient: 23 years later we used a similar experiment to prove that lipoid CAH was due to a mutation in a non-enzymatic protein (Lin et al. 1995) . Koizumi et al. (1977) also found that affected mitochondria failed to convert cholesterol to pregnenolone but were unable to account for Degenhart's findings. By this time it was clear that the conversion of cholesterol to pregnenolone was catalyzed by a mitochondrial cytochrome P450 enzyme, termed P450scc, (where scc denotes side chain cleavage), which functions as the terminal oxidase in a mitochondrial electron-transfer chain where NADPH donated electrons to a flavoprotein (adrenodoxin reductase) which then transferred them to an iron-sulfur protein (adrenodoxin) which in turn donated them to P450scc (Kimura & Suzuki 1965 , Omura et al. 1966 , Shikita & Hall 1973 ) (for review see Miller 1988) . Thus Koizumi examined the total P450 in the affected adrenal mitochondria in the only fashion then available, by carbon monoxide-induced difference spectra, and concluded that affected mitochondria had roughly half of the normal amount of total cytochrome P450. At that time it was known that steroid 11 -hydroxylase and 18-hydroxylase activities were also catalyzed by a mitochondrial P450, and as the affected mitochondria had normal 11 -/18-hydroxylase activity but failed to convert cholesterol to pregnenolone, Koizumi et al. (1977) logically concluded that the defect was an absence of cytochrome P450scc. This report 'established' that lipoid CAH was due to a lesion in P450scc, and this idea was not questioned until 1991. The cloning of the human P450scc cDNA (Chung et al. 1986 ) and gene (Morohashi et al. 1987 ) permitted testing of this hypothesis. Our preliminary examination of the P450scc gene in affected patients revealed no gross abnormalities (Matteson et al. 1986) . However, in 1991 we found normal P450scc gene sequences in two patients, and normal amounts of P450scc mRNA having a normal sequence in the gonadal tissue of one affected patient (Lin et al. 1991) . These observations thus proved that lipoid CAH was not due to mutations in P450scc or a component of the hypothetical '20,22 desmolase complex'. Despite our finding of normal P450scc gene and cDNA sequences in affected patients, the dominant view remained that lipoid CAH was due to a disorder of P450scc. This view appeared to be strengthened by the demonstration that rabbits having a syndrome of cortisol deficiency, neonatal death and lipid-laden adrenals that looked like the adrenals in lipoid CAH (Pang et al. 1992) had P450scc gene deletions (Yang et al. 1993) . However, two other groups confirmed our finding that the P450scc genes of lipoid CAH patients were normal (Sakai et al. 1994 , Fukami et al. 1995 , hence the CAH rabbits were not a model of human lipoid CAH.
When we found normal P450scc gene and cDNA sequences in lipoid CAH, we began to search for other candidate genes that might be affected. Northern blots showed that the adrenodoxin and adrenodoxin reductase mRNAs were of normal size and abundance (Lin et al. 1991) . Although we did not sequence their cDNAs, it seemed clear that subtle mutations in these proteins could not cause lipoid CAH, as adrenodoxin and adrenodoxin reductase also transfer electrons to the mitochondrial P450s involved in vitamin D and in bile acid biosynthesis, and these functions are normal in lipoid CAH patients. Therefore we began to consider whether lipoid CAH might be due to disruption of a factor involved in the transport of cholesterol from lipid droplets to mitochondria or from the outer mitochondrial membrane to P450scc. Unfortunately then, as now, it was not known exactly how cholesterol travels from lipid droplets to P450scc.
Search for the acute regulator of steroidogenesis
Between 1980 and 1995 many laboratories were searching for the 'acute regulator' of steroidogenesis (for review see Stocco & Clark 1996) . It was clear that adrenocorticotropin (ACTH) could induce adrenal steroidogenesis in a very rapid, cycloheximide-inhibitable fashion in all species studied: the 'acute response' (Stone & Hechter 1955 , Ferguson 1963 , Garren et al. 1965 , 1966 . Work in the late 1980s showed that ACTH, working through cAMP as its second messenger, induced the transcription of the genes for P450scc and other steroidogenic enzymes (for review see Waterman & Simpson 1989 , Moore & Miller 1991 . One group proposed that a short-lived, cycloheximide-sensitive DNA-binding protein, operationally termed steroid hormone inducing protein (SHIP) was involved in this process as a transcription factor (Waterman & Simpson 1989) . While it soon became clear that the action of cycloheximide did not affect transcription of the steroidogenic enzyme genes or the accumulation of their encoded mRNAs (Golos et al. 1987 , Picado-Leonard et al. 1988 , Mellon & Vaisse 1989 , Ringler et al. 1989 , it was still not clear exactly what cycloheximide was doing.
Many candidates for the 'acute regulator' were proposed, including sterol carrier protein 2 (Chandebhan et al. 1982 , Vahouny et al. 1983 , so-called steroidogenesis activator peptide and its presumed precursor, GRP-78 (Pedersen & Brownie 1983 , 1987 , Li et al. 1989 , and the peripheral benzodiazepine receptor (PBR) (Iida et al. 1989 , Papadopoulos 1993 ) and its presumed endogenous ligand termed endozepine or diazepam-binding inhibitor (DBI) (Yanagibashi et al. 1988 , Besman et al. 1989 . However, we found that the size and abundance of the mRNAs for all of these proteins were normal in lipoid CAH tissues (Lin et al. 1991) . Although the PBR/endozepine system probably plays a major role in cholesterol movement into mitochondria (Papadopoulos et al. 1997 ) the PBR gene sequence was also wholly normal in lipoid CAH (Lin et al. 1993) . Thus none of these factors was involved in lipoid CAH, and, on closer examination, none of them possessed the three required features of the 'acute regulator': (i) rapid inducibility by cAMP, (ii) short half-life evidenced by cycloheximide sensitivity, (iii) capacity to induce steroidogenesis (Stocco & Clark 1996) . However, another family of peptides, initially termed pp30, pp32, and pp37 (designating phosphoproteins of 30, 32, and 37 kDa) appeared to possess at least the characteristics of cAMPinducibility and cycloheximide-sensitivity (Pon & Orme-Johnson 1986 , Epstein & Orme-Johnson 1991 , Stocco & Sodemin 1991 ). Stocco's group purified one of these proteins, obtained a partial amino acid sequence, and then cloned it from mouse Leydig MA-10 cells. When they transferred its cDNA expression vector back into MA-10 cells it enhanced their steroidogenesis, engendering the name 'steroidogenic acute regulatory protein ', or StAR (Clark et al. 1994) . These studies were done in uninduced MA-10 cells, which have very little StAR, but the use of a steroidogenic host cell left some questions unanswered.
StAR, the acute regulator, is mutated in lipoid CAH
At this point the study of lipoid CAH and the study of the acute steroidogenic response came together, illuminating both fields. Our clinical studies showed that not all steroidogenic tissues were affected in lipoid CAH, as had been thought previously, but that the placenta's ability to synthesize progesterone from cholesterol remained intact in this disease (Saenger et al. 1995) . Thus a further characteristic of the gene that was mutated in lipoid CAH had to be that it was expressed in the adrenals and gonads, but not in the placenta (Saenger et al. 1995) ; expression in the fourth steroidogenic tissue, the brain (Mellon 1994) also seemed unlikely, as successfully treated patients with lipoid CAH did not have an apparent syndrome of a central nervous system cholesterol storage disease. In retrospect, it should not have been a surprise that placental biosynthesis of progesterone was unaffected in lipoid CAH, as progesterone is required for the maintenance of pregnancy. In human pregnancy, the mother's corpus luteum provides this progesterone during the first trimester, but the placenta is needed for progesterone biosynthesis in the second and third trimesters: maternal ovariectomy causes spontaneous abortion in the first trimester but not thereafter. Similarly, a severe lesion in fetal P450scc would disrupt placental progesterone synthesis and lead to early spontaneous abortion. By contrast, in rabbits, where P450scc gene deletions cause a lipoid CAH-like syndrome (Yang et al. 1993 ) the maternal corpus luteum provides the needed progesterone throughout pregnancy, so that disruption of placental steroidogenesis by a P450scc lesion is compatible with term pregnancy.
After its initial cloning from mouse MA-10 cells (Clark et al. 1994 ) work on StAR progressed rapidly through collaborations among the laboratories of Douglas Stocco, Jerome F Strauss III, and our laboratory. When Strauss's laboratory found that StAR was expressed in the adrenals and gonads but not in the placenta or brain (Sugawara et al. 1995a) , StAR immediately became the foremost candidate for the cause of lipoid CAH. At this time (autumn of 1994) our laboratory still had some of the cDNA that we had prepared from the gonadal tissue of a lipoid CAH patient, which we had used four years earlier to show that P450scc was unaffected (Lin et al. 1991) . As soon as the 5 and 3 ends of the normal human StAR cDNA were sequenced, we synthesized human StAR oligonucleotides and PCR-amplified the StAR cDNA from the gonadal cDNA of our index patient. We quickly found that the StAR cDNA was mutated in this patient, and then found mutations in the genomic DNA of three more patients, thus establishing that StAR mutations caused lipoid CAH (Lin et al. 1995 , Tee et al. 1995 .
While we had demonstrated that lipoid CAH patients were homozygous for StAR gene mutations, proof that these mutations caused the disease required a demonstration that these mutations could account for the phenotype, i.e. we needed an assay for StAR activity in transfected non-steroidogenic cells. We did this by examining the ability of StAR cDNA expression vectors to promote the synthesis of pregnenolone in COS-1 cells triply transfected with vectors for human P450scc, adrenodoxin and adrenodoxin reductase (Lin et al. 1995) . The results of these experiments were consistent in showing that StAR increased pregnenolone biosynthesis 8-fold while mutant StAR did not. However, we knew that the activity of P450scc was crucially dependent on the molar ratio of P450scc to adrenodoxin present in a cell (Zuber et al. 1988 , Harikrishna et al. 1993 ), hence we wished to fix the ratio of these two proteins to eliminate assay variability. We were able to do this easily because we had previously built a series of fusion proteins of P450scc, adrenodoxin, and adrenodoxin reductase (Harikrishna et al. 1993 , Black et al. 1994 . One of these, termed F2 (for fusion protein 2) which had the structure H 2 N-P450scc-adrenodoxin reductase-adrenodoxin-COOH, had a V max that was 5-fold greater than the natural P450scc, but at the expense of a higher K m (Michaelis constant), so that its catalytic constant (V max /K m ) was the same (Harikrishna et al. 1993) . By transfecting COS-1 cells with the F2 expression vector, we ensured that the three components of the P450scc system were always present equally, as this vector expressed a single covalent fusion protein. By the time we learned that lipoid CAH patients carried StAR mutations it was also known that soluble hydroxysterols were freely accessible to mitochondrial P450scc, and could bypass whatever mechanism the cell used to deliver cholesterol to P450scc (Toaff et al. 1982) . In fact hydroxysterols were widely used to gauge the net steroidogenic capacity of a cell system, without the need to consider cholesterol transport as a confounding factor. This then permitted us to assess the degree to which StAR's action transported the maximum amount of cholesterol that the cell could use.
Thus, we showed that cells transfected with the F2 fusion protein increased their steroidogenic capacity 8-fold when co-transfected with normal StAR but not with the StAR mutants found in lipoid CAH (Table 1) . Furthermore, this action of StAR could be bypassed by providing the transfected cells with the soluble hydroxysterol 22-OH cholesterol (Lin et al. 1995 , Sugawara et al. 1995a , Tee et al. 1995 . Thus StAR acted to facilitate the movement of cholesterol into mitochondria, but StAR's action was not required for the conversion of hydroxysterols. This experiment essentially recapitulated the experiment that Degenhart published in 1972: both the 22-OH cholesterol we used and the 20-OH cholesterol used by Degenhart et al. (1972) bypassed the absent action of StAR. However, Degenhart et al. could not interpret their results accurately as it was not then known that cholesterol required a cycloheximide-sensitive factor to enter mitochondria, or that the action of this factor could be circumvented by use of soluble hydroxysterol analogs of cholesterol. These initial transfection experiments proved that StAR acted to enhance cholesterol access to P450scc and that the StAR mutations found in lipoid CAH patients served as a gene knockout of nature, proving the essential role of this protein. But they also showed that P450scc or F2 could convert some cholesterol to pregnenolone in the absence of StAR (Table 1) . As we shall see later, this was a crucial observation in deducing our 'two-hit model' that now appears to explain the unusual clinical findings in lipoid CAH.
Clinical findings in lipoid CAH
The initial clinical reports of lipoid CAH appeared sporadically. Hauffa et al. published the first comprehensive review of this disease in 1985, 30 years after Prader's first report, and found only 32 proven cases in a search of the worldwide literature (only six of which were in English language publications), suggesting that lipoid CAH was very rare (Hauffa et al. 1985) . The true incidence of lipoid CAH is unknown, but it is clearly much higher in people of Japanese, Korean and Palestinian ancestry (Bose et al. 1996 ). Hauffa's review found that all the patients had phenotypically normal female external genitalia irrespective of chromosomal sex (indicating a severe defect in fetal testicular synthesis of testosterone), hyponatremia, hyperkalemia, low urinary 17-hydroxycorticosteroids and 17-ketosteroids (indicating a profound lesion in adrenal steroid biosynthesis), hyperpigmentation (due to overproduction of ACTH), and an excellent response to glucocorticoid and mineralocorticoid replacement. Fourteen of twenty-eight patients in whom the apparent genetic sex was reported appeared to be male (as indicated by karyotype, buccal smear, gonadal appearance or gonadal histology), consistent with autosomal recessive inheritance. Although only eleven of these first patients survived, both Kirkland et al. (1973) and Hauffa et al. (1985) showed that patients with lipoid CAH could survive to adulthood if diagnosed early in infancy and treated with appropriate glucocorticoid and mineralocorticoid replacement therapy. Hauffa et al. also pointed out the genetic clustering of lipoid CAH, with a remarkable 56% of the initial 32 patients being of Japanese heritage. Hauffa et al. (1985) also noted certain oddities in the clinical presentations and hormonal findings. Only 15 of 28 patients manifested clinical signs of adrenal insufficiency by 2 weeks of age, the time at which the salt-wasting crisis of severe 21-hydroxylase deficiency is usually apparent, and some affected patients did not become clinically ill until more than 3 months of age. Furthermore, many patients had low, rather than absent amounts of adrenal steroids in the newborn period, but these steroids were unmeasurable after a few years Data are from Lin et al. (1995) . Note that when the cholesterol endogenously present in the cell is the sole source of cholesterol, cells transfected with the two StAR mutants produce pregnenolone production at a level that is indistinguishable from that of cells transfected with the vector alone, showing that the mutants are inactive. However, this value is still 14% of the value seen in cells transfected with the wild-type StAR vector indicating that some steroidogenesis occurs in the absence of StAR. Note also that soluble 20 -hydroxycholesterol bypasses the action of StAR so that the production of pregnenolone is the same in all four transfections.
in surviving patients. Nevertheless, until quite recently, the conventional view of lipoid CAH was that it was due to a severe disorder in the cholesterol side-chain cleavage system, leading to the common (but incorrect) name '20-22 desmolase deficiency'. This deficiency was thought to ablate all adrenal and gonadal steroidogenesis, consistent with the wholly female external genitalia of affected 46,XY individuals. The low but measurable adrenal steroids found in many affected newborns were unexplained, and dismissed as representing transplacental maternal steroids, cross-reacting materials, or the result of 'partial blocks' in the enzymatic step. The generally later age of onset of the salt-wasting crisis in lipoid CAH compared with 21-hydroxylase deficiency was dismissed as evidence for unproven, putative salt-wasting effects of the high concentrations of 17-OH progesterone in 21-hydroxylase deficiency.
The clinical understanding of lipoid CAH has changed dramatically in the past few years. The demonstration that P450scc was not disordered in this disease (Lin et al. 1991) was the first step in correcting views of lipoid CAH. In 1994 Matsuo et al. presented most surprising findings, published only in abstract form, reporting that only 16 of 63 Japanese patients with lipoid CAH were 46,XX genetic females, and that all 5 who were over 13 years of age had spontaneous breast development and vaginal bleeding associated with serum estradiol levels ranging from 22 to 85 pg/ml (Matsuo et al. 1994) . This preliminary report raised important questions, but was largely overlooked until intensive study of the disease was triggered by the demonstration that StAR mutations caused lipoid CAH. We recently summarized the clinical findings in our index cases and described the clinical and molecular genetic findings in 15 additional, previously undescribed cases of lipoid CAH from 10 countries (Bose et al. 1996) . These findings and some additional previously unreported hormonal data on these patients are summarized in Table 2 . In addition Nakae et al. (1997) have recently reported similar clinical and molecular findings in another 19 Japanese patients. Our 20 affected infants were all of term gestation and of appropriate sizes for their gestational ages. Five infants had hypoglycemia and six had some form of neonatal respiratory difficulties, but true respiratory distress syndrome or hyaline membrane disease due to diminished production of pulmonary surfactant was not documented in any of these cases. Both neonatal hypoglycemia and neonatal respiratory distress syndrome might be associated with underproduction of cortisol during late gestation. The age of onset of symptoms of hyponatremia and hyperkalemia varied considerably, from 1 day to 2 months of age. Most infants who were tested had measurable levels of cortisol, and some 46,XY males had measurable testosterone, which failed to rise following tropic stimulation (Table 2) . Even more remarkably, many infants survived for an extended time without hormonal replacement therapy: among our 20 cases, treatment was not begun until after age 2 months in 7 infants, and one survived for 6 months without glucocorticoid or mineralocorticoid replacement. Only 2 of the 19 patients reported by Nakae et al. (1997) received initial treatment at or after 2 months of age, but one of these survived to 10 months before experiencing a saltwasting crisis (see 'genotype/phenotype correlations' below). Thus, while the adrenal lesion in lipoid CAH eventually becomes the most severe of any of the forms of CAH, some steroid synthesis persists in infancy and the onset of clinical symptoms may be delayed for quite some time. By contrast, all 46,XY patients with lipoid CAH reported to date have had wholly normal female external genitalia (except for Nakae's patient who became ill at 10 months of age), even though the age of onset of glucocorticoid and mineralocorticoid deficiencies varies substantially. Thus the testicular lesion appears to be more severe than the adrenal lesion, and manifests at a much earlier stage of development.
Mutations in the StAR gene and genotype/phenotype correlations
The molecular lesions in at least 40 patients with lipoid CAH have been identified (Lin et al. 1995 , Tee et al. 1995 , Bose et al. 1996 , 1997 , Fujieda et al. 1997 , Nakae et al. 1997 , Okuyama et al. 1997 ; these mutations and the activities of the corresponding mutant StAR proteins are summarized in Table 3 . Most patients are of Japanese or Korean ancestry, among whom the Q258X mutation accounts for about 70% of affected alleles. At least another two dozen patients have been reported in various abstracts and oral presentations, but the identified mutations largely duplicate those reported in Table 3 (including a preliminary report showing 10 of 10 affected Korean alleles carrying Q258 (Yoo 1997) ). We have devised rapid PCR-based restriction fragment length polymorphism diagnostic tactics for ten of these mutations, including the common Q258X mutation found in Japanese and Korean populations (Fig. 1) , and the R182L mutation found in Palestinian Arabs (Bose et al. 1996) .
Several points emerge from an analysis of these mutations (Fig. 2) . First, mutations can be found in any exon and even in introns; mutations causing premature translational termination or altering of the StAR reading frame are common, and, as they substantially alter the structure of the StAR protein, it is not surprising that these mutations result in no StAR activity (i.e. induce no greater than the backgound conversion of cholesterol to pregnenolone, which is generally about 14% of the StAR-assisted conversion). Secondly, all missense mutations (those that simply change one amino acid for another), are found in the carboxy-terminal 40% of the 285 amino acid StAR protein. Most of these amino acid changes (E169G, E169K, R182L, A218V, and R272) also totally eliminate StAR activity. However, two mutations were associated with some residual StAR activity; L275P and M225T respectively converted 24% and 44% as much cholesterol to pregnenolone as the wild-type StAR. After subtracting the StAR-independent background of 14% the L275P mutant retained 10% of activity and the M225T mutant retained 30% of activity. The L275P mutant was found in a compound heterozygote along with the mutation A218V, which may or may not also retain minimal activity, as we found its cholesterol-to-pregnenolone conversion was 20% (i.e. 6% above basal) (Bose et al. 1996) while Nakae et al. (1997) found a conversion of 14%, which is equal to background. The affected patient, #13 in Table 2 , had no clinical symptoms until 2 months of age and survived without treatment until 4 months, at which time the clinical picture (Na, 123 mEq/l; K, 6·9 mEq/l) was comparatively mild. The M225T mutant was found as a compound heterozygote with the common Japanese mutant Q258X (Nakae et al. 1997 ). This infant is the only established case of lipoid CAH in which a 46,XY patient had mild virilization of the external genitalia, consisting of mild cliteromegaly, minimal posterior labial fusion, and mild rugation of the labia. Because of these findings, this infant was followed closely and had normal basal and ACTH-stimulated cortisol values at 1 and 3 months of age, but eventually experienced a salt-losing crisis at 10 months, associated with hyponatremia, hyperkalemia, and grossly elevated ACTH and plasma renin values (Nakae et al. 1997, K Fujieda, personal communication) . Thus there appears to be an excellent correlation between the severity of the StAR mutation as assessed in vitro with the age of onset of a clinical salt-wasting crisis, and possibly also with genital virilization. An additional, initially unexpected phenotypic manifestation of lipoid CAH is that even the most severely affected 46,XX female patients undergo spontaneous feminization, breast development and cyclical vaginal bleeding at the usual age of puberty (Matsuo et al. 1994 , Bose et al. 1997 , Fujieda et al. 1997 ). This is not correlated with the molecular severity of the mutation, but was recently explained by our 'two-hit model' of the cellular pathophysiology of lipoid CAH (Bose et al. 1996) .
The two-hit model of lipoid CAH
Because virtually all of these infants had genetic lesions that were genetically and biochemically equivalent (Table 3) , we hypothesized that the variation in onset of symptoms had to reflect some other cellular event that was secondary to the genetic lesion. Clues came from our in vitro studies of the biology of P450scc and StAR, and from Matsuo's preliminary report of ovarian function in lipoid CAH patients (Matsuo et al. 1994) . We knew that all cells and tissues express the mRNAs for adrenodoxin (Picado-Leonard et al. 1988 ) and adrenodoxin reductase (Brentano et al. 1992) ; hence it was not surprising that COS-1 cells exhibited cholesterol side-chain cleavage activity when transfected only with a P450scc cDNA expression vector (Zuber et al. 1988 , Harikrishna et al. 1993 ) (for review see Miller 1995) . We also knew that incubating cells with soluble hydroxysterols resulted in more pregnenolone production than arose from endogenous cellular cholesterol (Lin et al. 1995 , Sugawara et al. 1995a . Soluble hydroxysterols provide maximal substrate availability to the P450scc system, and result in 2-to 3-fold greater production of pregnenolone than can be achieved in cells transfected with a StAR expression vector and stimulated with cAMP (Lin et al. 1995 , Sugawara et al. 1995a ,b, Tee et al. 1995 , Bose et al. 1996 . However, the key point was that some steroidogenesis persists in these transfected cells in the absence of StAR (Table 1 ). Thus we reasoned that the adrenals and gonads of patients with StAR mutations should retain a modest degree of steroidogenic capacity. This led us to introduce the concept that there are distinct StAR-dependent and StAR-independent modes of steroidogenesis (Bose et al. 1996) . The nature of this StAR-independent steroidogenesis remains unknown; it could be due to totally passive diffusion, but more likely involves the action of other StAR-like molecules. The recent demonstration that the carboxyterminus of MLN64 has a sequence similar to StAR, possesses StAR-like activity, and is expressed in the steroidogenic tissues that lack StAR (Watari et al. 1997 ) strongly supports this view. In addition to transfected cells in vitro, the placenta (Saenger et al. 1995) and brain (Mellon 1994) are examples of tissues that exhibit StAR-independent steroidogenesis in vivo. This conceptualization permitted us to propose an explanation for why some infants with lipoid CAH do not manifest clinical evidence of mineralocorticoid deficiency for several months, and why 46,XX genetic females with lipoid CAH undergo spontaneous feminization at the age of puberty (Matsuo et al. 1994 , Bose et al. 1997 , Fujieda et al. 1997 . The pathophysiology of lipoid CAH appears to result from two different cellular events (Bose et al. 1996) . First, mutations in the StAR protein prevent the acute steroidogenic response in the fetal testis and adrenal. This eliminates the StAR-dependent steroid response to tropic stimulation, but permits a modest level of StAR-independent steroidogenesis, as seen in the placenta or in COS-1 cells transfected with vectors expressing the P450scc system without StAR. The absence of tropicly-induced, StARdependent steroidogenesis results in persistently  1. Genetic diagnosis of the Q258X mutation commonly found in Japanese and Korean patients. Lane 1 shows a 100 bp ladder of molecular size markers. Exon 7 of the StAR gene can be amplified from genomic DNA by PCR using appropriate primers, such as S4 and AS1 (Lin et al. 1995) , which yield the 254 bp fragment shown in lane 2. The Q258X mutation changes the sequence ACCAGGT, which can be cleaved by EcoRII, BstNI or SexAI, to ACTAGGT, which is not cleaved. Lane 3 shows a homozygously affected patient, lanes 4 and 5 show the heterozygous parents and lane 6 shows an unaffected control. The presence of other EcoRII/BstNI sites in the 254 bp fragment results in all subjects having smaller fragments than the undigested PCR product, providing an internal control for the enzyme digestion (Bose et al. 1996) . elevated concentrations of the tropic hormones, ACTH and gonadotropins, stimulating further uptake of low density lipoprotein (LDL) cholesterol and of endogenous synthesis of cholesterol. Secondly, the accumulation of unused cholesterol and cholesterol esters in affected steroidogenic cells damages the cell, either through physical engorgement with lipid droplets or as a consequence of toxic effects of sterol auto-oxidation products. This eventually damages the cell, disrupting the basal, StAR-independent steroidogenesis (Fig. 3) . Thus the fetal testis, which undergoes robust tropic stimulation by human chorionic gonadotropin in early gestation, is severely affected in early gestation, so that there is no evidence of any virilization, except in a single patient who retained 30% of StAR activity on one allele carrying M225T (Nakae et al. 1997) . Similarly, the fetal zone of the adrenal, which normally makes huge amounts of dehydroepiandrosterone (DHEA) for conversion to estriol by the placenta, is also profoundly affected; virtually no DHEA is produced, leading to the minimal estriol concentrations in the plasma of women carrying a lipoid CAH fetus (Saenger et al. 1995) . By contrast, the definitive zone of the fetal adrenal makes relatively small amounts of steroids in utero, but apparently develops into the adrenal zonae glomerulosa and fasciculata (which respectively produce mineralocorticoids and glucocorticoids) following birth (Mesiano et al. 1993) . At birth these zones are not yet fully destroyed by the accumulation of cholesterol esters, leading to the modest but detectable levels of steroid hormones typically seen in affected infants, and permitting short-term survival until the accumulation of cholesterol esters finally ablates all residual StARindependent adrenal steroidogenesis. In fact, two early reports noted that the histopathological changes of the adrenal in lipoid CAH were confined to the fetal zone and spared the definitive zone (Dohm 1958 , Moragas & Ballabriga 1969 .
It is not clear what determines the length of time an infant with lipoid CAH can survive before experiencing a salt-wasting crisis. Certainly the few infants with less severe StAR mutations survive longer, as described above. However, there remains substantial variation in the time of onset of clinical salt loss and the time of survival without hormonal replacement therapy among those infants who have the most severe StAR lesions. We would suggest that one factor might be the environment into which the affected infant is born. Affected infants born in the hot arid climates of the Middle East appeared to experience salt loss sooner than those born in cool, moist northerly climates. A hot dry climate favors salt and water loss and decreased intravascular  2. Diagram of the human StAR gene. The sizes of the introns and exons, and the base numbering system, are as described by Sugawara et al. (1995b) . The StAR mutations published as of mid 1997 are shown; all of the amino acid replacement mutations shown have been studied in transfected cells by Bose et al. (1996) or Nakae et al. (1997) using the F2 P450scc fusion protein of Harikrishna et al. (1993) .
Lipoid CAH-StAR knockout ·    235 volume, driving a greater tropic stimulation of definitive zone cells destined to become the zona glomerulosa. This tropic stimulation by the renin/ angiotensin system might begin prenatally in a mother with chronically compensated hypovolemia, and would favor the more rapid destruction of cells able to make aldosterone.
However, the most interesting prediction of the two-hit model of lipoid CAH concerns the steroidogenic capacity of the ovary. In contrast to the fetal testis and fetal adrenal, the fetal ovary lacks steroidogenic enzymes and steroidogenic capacity (Voutilainen & Miller 1986 ) consistent with a lack of estrogen action in normal female sexual differentiation (Grumbach & Conte 1992) . As the ovary remains unstimulated until puberty, the ovary affected with lipoid CAH does not accumulate cholesterol esters. The onset of puberty, which is an event in the hypothalamus that is independent of sex steroids (Grumbach & Styne 1992) , produces the gonadotropins that stimulate the maturation of individual ovarian follicles. These stimulated follicles remain capable of StAR-independent steroidogenesis leading to low levels of ovarian estrogen synthesis in affected 46,XX females. The accumulation of cholesterol esters eventually destroys the StARindependent steroidogenic capacity of both the granulosa and theca cells of the affected follicles. However, previously unstimulated primordial follicles that remain undamaged are recruited in subsequent monthly cycles, permitting a low level of estrogen synthesis to continue. This results in feminization, with breast development and the minimal amounts of pubic and axillary hair that result from low levels of ovarian androgens in the absence of adrenal androgens. Because monthly  3. Model of lipoid CAH in an adrenal cell. (A) In the normal cell, cholesterol is derived from endogenous synthesis from acetyl coenzyme A in the endoplasmic reticulum (ER), from cholesterol esters stored in lipid droplets, and from LDL cholesterol which, after receptor-mediated endocytosis, is processed in lysosomes before it is used or stored in lipid droplets. Cholesterol is transported to the outer mitochondrial membrane by ill-defined processes involving the cytoskeleton (for review see Hall 1997). The rate-limiting step in steroidogenesis is the movement of cholesterol from the outer to the inner mitochondrial membrane; this can be promoted by StAR, but may also be mediated by StAR-independent mechanisms. Thus the net synthesis of steroid is due to both StAR-dependent and StAR-independent means. (B) In the absence of StAR, as in early lipoid CAH or in a placental cell, StAR-independent mechanisms can still move some cholesterol into the mitochondria, resulting in a low level of steroidogenesis. In an affected adrenal cell this results in increased corticotropin secretion, stimulating further production of cholesterol and its accumulation as cholesterol esters in lipid droplets. (C) As lipid droplets accumulate they engorge the cell, damaging its cytoarchitecture both through physical displacement and by the chemical action of cholesterol auto-oxidation products. Steroidogenic capacity is destroyed and consequently tropic stimulation continues. In the ovary, follicular cells remain unstimulated and hence undamaged until they are recruited at the beginning of each cycle. Small amounts of estradiol are produced, analogously to panel B, effecting phenotypic feminization and withdrawal bleeding, but the cycles are anovulatory, resulting in infertility and progressive hypergonadotropic hypogonadism. cyclicity is driven by the hypothalamus, this estrogen synthesis will cycle normally, so that estrogen withdrawal bleeding of the uterus will occur monthly in the pattern of normal menses. However, in the absence of StAR the ovary is incapable of a progesterone surge, so that the cycles should be anovulatory (Bose et al. 1996 (Bose et al. , 1997 . This has recently been demonstrated by multiple measurements of estradiol, progesterone, and the gonadotropins during several monthly cycles in two affected 46,XX patients (Fujieda et al. 1997) . Because the amounts of sex steroids that are produced are low, these patients have hypergonadotropic hypogonadism. In the untreated state, this hypergonadotropic state may induce the formation of large ovarian cysts, which can undergo torsion leading to a fatal outcome. Thus we recommend that 46,XX genetic female patients with lipoid CAH should be treated with oral contraceptives or medroxyprogesterone to suppress the gonadotropins and development of cysts (Bose et al. 1997) .
Unanswered questions
The identification of StAR as the factor responsible for lipoid CAH ends the 40-year quest for the cause of this disease, and the identification of common, population-specific mutations will permit rapid accurate diagnosis in the newborn and ascertainment of the heterozygous carrier state in those populations (e.g. Japanese, Koreans, and Palestinians) (Bose et al. 1996) . However some questions remain. In our recent survey of lipoid CAH patients, we found one who had no StAR mutation (Bose et al. 1996) . While it remains possible that we missed a StAR mutation in the unsequenced introns or regulatory regions of this patient's StAR gene, this patient also raises the possibility that there may be other factors which, when mutated, create a syndrome that is clinically indistinguishable from lipoid CAH. We now have identified a second, as yet unreported patient in whom we could not find a StAR mutation, further suggesting this possibility. As more patients are diagnosed, it remains crucial to perform imaging studies of the adrenals, as the diagnosis of lipoid CAH cannot be established in a 46,XX patient in the absence of massive adrenal enlargement in the newborn (Hauffa et al. 1985) . If such imaging studies are not performed, other disorders, such as congenital adrenal hypoplasia (Guo et al. 1994 , Zanaria et al. 1994 , may be mis-diagnosed as lipoid CAH. An unresolved diagnostic issue is whether or not the massive adrenal enlargement seen in lipoid CAH newborns persists in successfully treated patients, or regresses with age; if it regresses, the retrospective diagnosis of lipoid CAH in treated 46,XX patients is not possible without molecular genetic examination of the StAR gene. A hypothetical lesion in the transcription factor SF-1, which is required for adrenal and gonadal development in the rodent (Luo et al. 1994) , might also be predicted to produce a similar phenotype, but no human SF-1 mutations have been reported to date. Thus, while finding StAR mutations in most patients examined certainly establishes StAR as the predominant cause of the lipoid CAH phenotype, it remains possible that mutations in other genes may produce a hormonally and clinically indistinguishable phenotype. Identifying the responsible genes would be of substantial interest.
Secondly, the mechanism of StAR's action remains unknown. The early suggestion that it facilitated cholesterol movement from the outer to the inner mitochondrial membrane by forming contact sites between the two as a result of its movement into the mitochondria (Stocco & Clark 1996) has been disproven. Although StAR has a mitochondrial leader peptide and is imported into mitochondria, the StAR protein remains wholly active when this peptide is removed, prohibiting StAR's entry into the mitochondria, and immunoelectron microscopy shows that biologically active StAR lacking this leader localizes to the outer mitochondrial membrane (Arakane et al. 1996) . It seems likely that cytoplasmic StAR interacts with one or more proteins on the outer mitochondrial membrane, possibly in a fashion analogous to a ligand and its receptor. Such receptor binding might trigger the assembly or opening of a cholesterol channel between the outer and inner membranes, and such channels may yet be found at contact sites. It is not clear what that receptor might be, or what might be the clinical consequences of mutations in it. The evidence that the mitochondrial benzodiazepine receptor complex participates in steroidogenesis (Papadopoulos 1993 , Papadopoulos et al. 1997 indicates that a careful examination of potential interactions between StAR and this receptor complex is needed.
Thirdly, the sex ratio of lipoid CAH remains unclear. The StAR gene is on chromosome 8pl1·2 (Sugawara et al. 1995a ), therefore lipoid CAH should exhibit autosomal recessive inheritance, affecting an equal number of genetic males and females. Although Hauffa et al. (1985) found a perfect 14:14 ratio of 46,XY genetic males and 46,XX genetic females affected with lipoid CAH and Nakae et al. (1997) found a ratio of 9:10, Matsuo et al. (1994) reported an XY/XX ratio of 47:16, and we found a ratio of 18:3 (Bose et al. 1996) . Thus some reports have found a preponderance of affected 46,XY individuals. There is no apparent reason for this: affected individuals of both genetic sexes will have the same phenotypic appearance and hormonal findings in infancy, and hence there should be no ascertainment bias. An effect of StAR on 23,X sperm seems unlikely but cannot be excluded. Thus the syndrome of congenital lipoid adrenal hyperplasia has yet to reveal all of its secrets.
